Tumor characteristics and treatment details of patients undergoing LTE for esophageal cancer
| n (%) . | . | |
|---|---|---|
| Preoperative treatment | ||
| Surgery alone | 104 (13.4) | |
| Neoadjuvant chemotherapy | 513 (65.9) | |
| Neoadjuvant chemoradiotherapy | 162 (20.8) | |
| Missing | 14 | |
| Anastomosis level | ||
| Thoracic | 719 (90.8) | |
| Cervical | 73 (9.2) | |
| Missing | 1 | |
| Tumor free resection margin† | ||
| Yes (R0) | 707 (89.8) | |
| No (R1) | 77 (9.8) | |
| No (R2) | 3 (0.4) | |
| Missing | 6 | |
| Pathologic tumor stage | ||
| (y)pT0 (complete histologic response) | 74 (9.5) | |
| (y)pT1 | 94 (12.0) | |
| (y)pT2 | 120 (15.3) | |
| (y)pT3 | 422 (53.9) | |
| (y)pT4a | 73 (9.3) | |
| (y)pTx | 10 | |
| Pathologic nodal stage | ||
| (y)pN0 | 333 (42.6) | |
| (y)pN1 | 177 (22.6) | |
| (y)pN2 | 133 (17.0) | |
| (y)pN3 | 139 (17.8) | |
| (y)pNx | 11 | |
| Number of resected lymph nodes, median (IQR) | 25 (18–35) | |
| Number of metastatic lymph nodes, median (IQR) | 1 (0–4) | |
| n (%) . | . | |
|---|---|---|
| Preoperative treatment | ||
| Surgery alone | 104 (13.4) | |
| Neoadjuvant chemotherapy | 513 (65.9) | |
| Neoadjuvant chemoradiotherapy | 162 (20.8) | |
| Missing | 14 | |
| Anastomosis level | ||
| Thoracic | 719 (90.8) | |
| Cervical | 73 (9.2) | |
| Missing | 1 | |
| Tumor free resection margin† | ||
| Yes (R0) | 707 (89.8) | |
| No (R1) | 77 (9.8) | |
| No (R2) | 3 (0.4) | |
| Missing | 6 | |
| Pathologic tumor stage | ||
| (y)pT0 (complete histologic response) | 74 (9.5) | |
| (y)pT1 | 94 (12.0) | |
| (y)pT2 | 120 (15.3) | |
| (y)pT3 | 422 (53.9) | |
| (y)pT4a | 73 (9.3) | |
| (y)pTx | 10 | |
| Pathologic nodal stage | ||
| (y)pN0 | 333 (42.6) | |
| (y)pN1 | 177 (22.6) | |
| (y)pN2 | 133 (17.0) | |
| (y)pN3 | 139 (17.8) | |
| (y)pNx | 11 | |
| Number of resected lymph nodes, median (IQR) | 25 (18–35) | |
| Number of metastatic lymph nodes, median (IQR) | 1 (0–4) | |
†According to the American definition for R0 resection.
Tumor characteristics and treatment details of patients undergoing LTE for esophageal cancer
| n (%) . | . | |
|---|---|---|
| Preoperative treatment | ||
| Surgery alone | 104 (13.4) | |
| Neoadjuvant chemotherapy | 513 (65.9) | |
| Neoadjuvant chemoradiotherapy | 162 (20.8) | |
| Missing | 14 | |
| Anastomosis level | ||
| Thoracic | 719 (90.8) | |
| Cervical | 73 (9.2) | |
| Missing | 1 | |
| Tumor free resection margin† | ||
| Yes (R0) | 707 (89.8) | |
| No (R1) | 77 (9.8) | |
| No (R2) | 3 (0.4) | |
| Missing | 6 | |
| Pathologic tumor stage | ||
| (y)pT0 (complete histologic response) | 74 (9.5) | |
| (y)pT1 | 94 (12.0) | |
| (y)pT2 | 120 (15.3) | |
| (y)pT3 | 422 (53.9) | |
| (y)pT4a | 73 (9.3) | |
| (y)pTx | 10 | |
| Pathologic nodal stage | ||
| (y)pN0 | 333 (42.6) | |
| (y)pN1 | 177 (22.6) | |
| (y)pN2 | 133 (17.0) | |
| (y)pN3 | 139 (17.8) | |
| (y)pNx | 11 | |
| Number of resected lymph nodes, median (IQR) | 25 (18–35) | |
| Number of metastatic lymph nodes, median (IQR) | 1 (0–4) | |
| n (%) . | . | |
|---|---|---|
| Preoperative treatment | ||
| Surgery alone | 104 (13.4) | |
| Neoadjuvant chemotherapy | 513 (65.9) | |
| Neoadjuvant chemoradiotherapy | 162 (20.8) | |
| Missing | 14 | |
| Anastomosis level | ||
| Thoracic | 719 (90.8) | |
| Cervical | 73 (9.2) | |
| Missing | 1 | |
| Tumor free resection margin† | ||
| Yes (R0) | 707 (89.8) | |
| No (R1) | 77 (9.8) | |
| No (R2) | 3 (0.4) | |
| Missing | 6 | |
| Pathologic tumor stage | ||
| (y)pT0 (complete histologic response) | 74 (9.5) | |
| (y)pT1 | 94 (12.0) | |
| (y)pT2 | 120 (15.3) | |
| (y)pT3 | 422 (53.9) | |
| (y)pT4a | 73 (9.3) | |
| (y)pTx | 10 | |
| Pathologic nodal stage | ||
| (y)pN0 | 333 (42.6) | |
| (y)pN1 | 177 (22.6) | |
| (y)pN2 | 133 (17.0) | |
| (y)pN3 | 139 (17.8) | |
| (y)pNx | 11 | |
| Number of resected lymph nodes, median (IQR) | 25 (18–35) | |
| Number of metastatic lymph nodes, median (IQR) | 1 (0–4) | |
†According to the American definition for R0 resection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
